Trial Profile
A Randomized, Double-blind, Two-arm, Parallel-group, Single Dose Study to Compare the Pharmacokinetics, Safety and Immunogenicity of Two Formulations of Trastuzumab (CT-P6 and US-licensed Herceptin) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Apr 2019
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer; Gastric cancer
- Focus Pharmacokinetics
- Sponsors Celltrion
- 24 Aug 2016 Status changed from recruiting to completed.
- 13 Feb 2016 New trial record